Suraksha Diagno.

Why is Suraksha Diagnostic Ltd falling/rising?

As of 09-Aug, Suraksha Diagnostic Ltd's stock price is at 250.10, reflecting a decline and a bearish trend, underperforming the sector. The stock has dropped 15.49% over the past year, influenced by poor financial results and negative market sentiment.

As of 09-Aug, Suraksha Diagnostic Ltd's stock price is falling, currently at 250.10, reflecting a decrease of 1.65 (-0.66%). The stock has underperformed relative to the sector today by 1.41% and has experienced a trend reversal, falling after two consecutive days of gains. Additionally, the stock touched an intraday low of Rs 246.45, marking a decline of 2.11%.<BR><BR>Over the past week, the stock has decreased by 0.64%, while the benchmark Sensex has increased by 0.52%. In the last month, the stock has dropped by 7.15%, contrasting with a slight gain of 0.41% in the Sensex. Year-to-date, Suraksha Diagnostic Ltd has seen a decline of 6.75%, although it has outperformed the Sensex, which has fallen by 7.89%. However, the one-year performance is concerning, with the stock down 15.49%, significantly underperforming the Sensex's decline of 2.63%.<BR><BR>The stock is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Despite a rise in investor participation, with delivery volume increasing by 7.92% against the 5-day average, the overall sentiment remains negative due to recent poor financial results. The company reported a significant drop in profit after tax (PAT) of 24.6% compared to the previous four-quarter average, alongside a low operating profit to interest ratio of 6.22 times.<BR><BR>In summary, the combination of recent financial underperformance, a bearish trend in stock price relative to moving averages, and negative market sentiment contribute to the decline in Suraksha Diagnostic Ltd's stock price.

Which are the latest news on Suraksha Diagno.?

What does Suraksha Diagno. do?

Suraksha Diagnostic Ltd is a micro-cap healthcare services company, incorporated in 2005, with net sales of 81 Cr and a net profit of 6 Cr as of March 2026. Key financial metrics include a P/E ratio of 43.00 and a market cap of INR 1,404 Cr.

Overview:<BR>Suraksha Diagnostic Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History:<BR>The company was incorporated in 2005 as Suraksha Diagnostic Private Limited and later converted to a public limited company, changing its name to Suraksha Diagnostic Limited. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 81 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 6 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 1,404 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 43.00<BR>- Industry P/E: 60<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.42<BR>- Return on Equity: 13.15%<BR>- Price to Book: 5.75<BR><BR>Contact Details:<BR>Registrar Address: Not available.

How big is Suraksha Diagno.?

As of 10th June, Suraksha Diagnostic Ltd has a market capitalization of 1,404.00 Cr and reported net sales of 310.42 Cr and net profit of 32.19 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Suraksha Diagnostic Ltd has a market capitalization of 1,404.00 Cr, categorized as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 310.42 Cr, while the sum of Net Profit for the same period is 32.19 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 211.24 Cr, and Total Assets amount to 333.52 Cr.

Who are the peers of the Suraksha Diagno.?

Suraksha Diagno.'s peers include Thyrocare Tech., Suven Life Sciences, Vimta Labs, Krsnaa Diagnostics, Laxmi Dental, Tarsons Products, One Global Services, and 3B Blackbio. In terms of management risk, growth, and capital structure, Suraksha Diagno. shows good performance relative to most peers, with a 1-year return of -19.20%.

Peers: The peers of Suraksha Diagno. are Thyrocare Tech., Suven Life Scie., Vimta Labs, Krsnaa Diagnost., Laxmi Dental, Tarsons Products, One Global Serv, and 3B Blackbio.<BR><BR>Quality Snapshot: Excellent management risk is observed at Thyrocare Tech. and Suraksha Diagno., while Average management risk is found at Vimta Labs, Krsnaa Diagnost., Laxmi Dental, One Global Serv, 3B Blackbio, and the rest. Below Average management risk is noted at Suven Life Scie. and Tarsons Products. Good growth is seen at Suraksha Diagno. and Laxmi Dental, while Average growth is found at Vimta Labs, Krsnaa Diagnost., and the rest. Below Average growth is noted at Thyrocare Tech., Suven Life Scie., Tarsons Products, and 3B Blackbio. Excellent capital structure is observed at Thyrocare Tech., Vimta Labs, Krsnaa Diagnost., One Global Serv, and 3B Blackbio, while Good capital structure is found at Suraksha Diagno. and Laxmi Dental, and Below Average capital structure is noted at Suven Life Scie. and Tarsons Products.<BR><BR>Return Snapshot: One Global Serv has the highest 1-year return at 104.99%, while Laxmi Dental has the lowest at -48.44%. Suraksha Diagno.'s 1-year return is -19.20%, which is higher than Laxmi Dental's but lower than One Global Serv's. Additionally, the peers with negative six-month returns include Krsnaa Diagnost., Laxmi Dental, Tarsons Products, and 3B Blackbio.

Should I buy, sell or hold Suraksha Diagnostic Ltd?

Are Suraksha Diagnostic Ltd latest results good or bad?

Suraksha Diagnostic Ltd's latest results show strong revenue growth with record net sales of ₹81.41 crores, up 25.07% year-on-year. However, profitability has declined significantly, with net profit falling 16.49% quarter-on-quarter, raising concerns about operational efficiency.

Suraksha Diagnostic Ltd's latest results present a mixed picture. On the positive side, the company achieved record net sales of ₹81.41 crores, reflecting a sequential growth of 4.79% and a year-on-year increase of 25.07%. This indicates strong demand for its diagnostic services and effective market penetration.<BR><BR>However, profitability has come under significant pressure. The net profit for the quarter fell to ₹6.28 crores, down 16.49% quarter-on-quarter and 15.02% year-on-year. Additionally, both the operating profit margin and the profit after tax (PAT) margin contracted, with the PAT margin dropping to 7.57% from 9.32% in the previous quarter. Rising interest costs and a higher effective tax rate have contributed to these declines, raising concerns about the company's operational efficiency and cost management.<BR><BR>In summary, while the revenue growth is commendable, the sharp decline in profitability metrics suggests underlying challenges that could impact the company's financial health moving forward.

When is the next results date for Suraksha Diagnostic Ltd?

The next results date for Suraksha Diagnostic Ltd is 21 May 2026.

The next results date for Suraksha Diagnostic Ltd is scheduled for 21 May 2026.

Is Suraksha Diagno. overvalued or undervalued?

As of October 14, 2025, Suraksha Diagnostics is considered overvalued with a PE ratio of 45.39, a Price to Book Value of 7.08, and an EV to EBITDA of 18.26, all significantly above industry norms, while its stock has underperformed the Sensex with a year-to-date return of -22.4%.

As of 14 October 2025, the valuation grade for Suraksha Diagnostics has moved from fair to expensive, indicating a shift in perception regarding its market value. The company is currently considered overvalued. Key ratios highlight this assessment: the PE ratio stands at 45.39, the Price to Book Value is 7.08, and the EV to EBITDA is 18.26, all of which are significantly higher than industry norms.<BR><BR>In comparison to its peers, Suraksha Diagnostics' PE ratio is notably lower than that of Max Healthcare, which has a PE of 93.68, and higher than Apollo Hospitals, which is valued at 70.7. The PEG ratio for Suraksha is 0.00, suggesting a lack of growth expectations compared to its price, further reinforcing the overvaluation stance. Additionally, the company's stock has underperformed against the Sensex, with a year-to-date return of -22.4% compared to the Sensex's 4.98%, which underscores the potential disconnect between its current valuation and market performance.

How has been the historical performance of Suraksha Diagno.?

Suraksha Diagno has shown positive financial growth over the past two years, with net sales increasing to 252.09 Cr in March 2025 from 218.71 Cr in March 2024, and profit after tax rising to 30.98 Cr from 23.13 Cr, reflecting improved profitability and a stable financial position.

Answer:<BR>The historical performance of Suraksha Diagno shows a positive trend in key financial metrics over the past two years.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Suraksha Diagno reported net sales of 252.09 Cr, an increase from 218.71 Cr in March 2024. The total operating income mirrored this growth, reaching 252.09 Cr, while total expenditure (excluding depreciation) rose to 170.85 Cr from 148.64 Cr. Operating profit, excluding other income, improved to 81.24 Cr from 70.07 Cr, leading to an operating profit margin of 32.23%, slightly up from 32.04%. Profit before tax also saw a significant increase to 41.41 Cr from 31.45 Cr, resulting in a profit after tax of 30.98 Cr, compared to 23.13 Cr the previous year. This reflects a PAT margin increase to 12.29% from 10.58%. The company's total assets grew to 333.52 Cr from 300.20 Cr, while total liabilities increased to 333.52 Cr from 300.20 Cr, indicating a stable financial position. Cash flow from operating activities improved to 63.00 Cr from 60.00 Cr, contributing to a consistent closing cash balance of 2.00 Cr over the last two years. Overall, Suraksha Diagno has demonstrated solid growth in revenue and profitability, alongside a stable asset and liability structure.

Is Suraksha Diagno. technically bullish or bearish?

As of June 23, 2025, the market for Suraksha Diagno is in a neutral stance with no clear direction, as indicated by mixed signals from key technical indicators like MACD, RSI, and moving averages.

As of 23 June 2025, the technical trend has changed from mildly bullish to sideways. The current stance is neutral, reflecting a lack of clear direction. The MACD shows no signal on both the weekly and monthly time frames, while the RSI also indicates no signal on the weekly and monthly. The Bollinger Bands are mildly bullish on the weekly but do not provide strong confirmation. Moving averages, KST, Dow Theory, and OBV show no trends, further supporting the neutral stance. Overall, the indicators suggest indecision in the market for Suraksha Diagno.

Who are the top shareholders of the Suraksha Diagno.?

The top shareholders of Suraksha Diagno include Ritu Mittal with 15.89%, Orbimed Asia II Mauritius Limited at 12.88%, mutual funds with 19.26%, foreign institutional investors holding 14.46%, and individual investors at 13.52%.

The top shareholders of Suraksha Diagno include the promoters, who hold the majority of shares. The promoter with the highest holding is Ritu Mittal, owning 15.89%. Additionally, Orbimed Asia II Mauritius Limited is the highest public shareholder with a stake of 12.88%. Mutual funds collectively hold 19.26% through 8 schemes, while foreign institutional investors (FIIs) hold 14.46% across 10 entities. Individual investors account for 13.52% of the shareholding.

Has Suraksha Diagno. declared dividend?

No Dividend History Available